UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2007
3 months
3 months
6 months
6 months
Year
PARTICULARS
ended
ended
ended
Ended
ended
9/30/2007
9/30/2006
9/30/2007
9/30/2006
31.03.07
Unaudited
Unaudited
Unaudited
Unaudited
Audited
Gross Sales/Operational Income
11000.61
7447.73
21263.51
12584.60
35610.58
Less Excise Duty
137.36
158.62
357.55
337.49
689.92
Net Sales/Operational Income
10863.25
7289.11
20905.96
12247.11
34920.65
Others Income
262.37
4.45
567.62
434.91
286.20
TOTAL EXPENDITURE :
9127.99
5910.32
17673.80
10012.24
28851.37
(a) (Increase)/decrease in stock in trade
257.30
(316.71)
90.00
(728.15)
(1254.16)
(b) Consumption of Raw Material
7291.11
4740.63
14500.91
7762.09
23953.77
(c) Staff Cost
236.02
200.65
511.72
393.47
907.93
(d) Other expenditure
1343.56
1285.75
2571.17
2584.83
5243.83
Interest
645.87
536.92
1340.02
1024.65
2587.57
Depreciation
386.48
283.51
758.70
573.27
1224.33
Profit(+)/Loss(-) before tax
965.28
562.81
1701.06
1071.86
2543.59
Provision for taxation
109.10
73.52
192.19
135.64
320.05
Provision for fringe benefit tax
2.35
4.07
4.79
5.45
14.05
Net Profit/Loss before Deferred Tax
853.83
485.22
1504.08
930.77
2209.49
Provision for deferred tax
133.72
35.00
250.72
57.16
273.11
Net Profit/Loss
720.11
450.21
1253.36
873.61
1936.38
Paid up Equity Share Capital
2212.00
2283.60
Reserve excluding revaluation reserves
18370.69
18875.39
EPS Rs. Basic
3.15
2.05
5.49
3.98
8.72
Diluted
3.02
2.05
4.95
3.98
8.62
Aggregated on Non-Promoters Shareholding
No. of Shares
15735204
15704594
15704594
% of Shareholding
68.91%
68.77%
68.77%
Notes:
1
During the Quarter under review the total turnover of Company increased by 49%. The Net Profit after tax has increased by 60% over the corresponding figures of previous year quarter.
2
Company has received the USFDA approval for its API Manufacturing facilities situated at Derabassi, Punjab.
3
Information on Investor Complaints for the quarter: Opening Balance Nil, Received 5, Redressed 4, closing Balance 1.
4
The previous period figures have been re-grouped and re-arranged wherever necessary.
5
The Company is exclusively in the Pharmaceutical business segment.
6
The above results were taken on record by the Board of Directors in its meeting held on 29th October, 2007.
For Ind-Swift Laboratories Limited
Sd/-
Sd/-
Place:Chandigarh
(N.R.MUNJAL)
(V.K.MEHTA)
Date: 29th October, 2007
Managing Director
Jt.Managing Director
To know about our Formulation Division, please visit us at Ind-Swift Limited, our other group company.
